Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.
Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, Dolling D, Patel S, Dahl M, Eudicone JM, Friberg L, Ouwens M, Antunes MO, Connelly KA, Madrini V Jr, Kuthi L, Lala A, Lorenzo M, Guimarães PO, Marcos MC, Merkely B, Nuñez J, Squire I, Václavík J, Wranicz J, Petrie MC.
Kosiborod MN, et al. Among authors: lala a.
J Am Coll Cardiol. 2025 Mar 18;85(10):971-984. doi: 10.1016/j.jacc.2024.11.014. Epub 2024 Nov 18.
J Am Coll Cardiol. 2025.
PMID: 39566872
Free article.
Clinical Trial.
Exploratory endpoints included a composite of adjudicated cardiovascular death or worsening heart failure (HF) events (hospitalizations and urgent visits). ...Adverse events (64% vs 63%) and serious adverse events (23% vs 22%) were balanced between SZC and placebo, respect …
Exploratory endpoints included a composite of adjudicated cardiovascular death or worsening heart failure (HF) events (hospitalizatio …